Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE DES VOSGES : revenue, balance sheet and financial ratios

SELARL PHARMACIE DES VOSGES is a French company founded 24 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in STRASBOURG (67000), this company of category PME shows in 2017 a revenue of 2.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE DES VOSGES (SIREN 441914512)
Indicator 2020 2019 2018 2017
Revenue N/C N/C N/C 2 823 013 €
Net income 89 729 € 89 501 € 86 733 € 95 869 €
EBITDA N/C N/C N/C 176 569 €
Net margin N/C N/C N/C 3.4%

Revenue and income statement

In 2020, SELARL PHARMACIE DES VOSGES generates positive net income of 90 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2020: 96 k€ -> 90 k€.

Net income (2020) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

89 729 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 92%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2020) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

91.708%

Financial autonomy (2020) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

43.865%

Asset age ratio (2020) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

13.6%

Solvency indicators evolution
SELARL PHARMACIE DES VOSGES

Sector positioning

Debt ratio
91.71 2020
2018
2019
2020
Q1: 33.2
Med: 96.78
Q3: 238.43
Good -6 pts over 3 years

In 2020, the debt ratio of SELARL PHARMACIE DES VOSGES (91.71) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
43.87% 2020
2018
2019
2020
Q1: 23.59%
Med: 41.65%
Q3: 61.95%
Good +6 pts over 3 years

In 2020, the financial autonomy of SELARL PHARMACIE DES VOSGES (43.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 94.61. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2020) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

94.613

Liquidity indicators evolution
SELARL PHARMACIE DES VOSGES

Sector positioning

Liquidity ratio
94.61 2020
2018
2019
2020
Q1: 133.12
Med: 181.89
Q3: 251.9
Watch

In 2020, the liquidity ratio of SELARL PHARMACIE DES VOSGES (94.61) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 123 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 927 days. Excellent situation: suppliers finance 804 days of the operating cycle (retail model).

Operating WCR (2020) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2020) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

123 j

Supplier credit (2020) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

927 j

Inventory turnover (2020) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE DES VOSGES

Positioning of SELARL PHARMACIE DES VOSGES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 180 transactions of similar company sales in 2020, the value of SELARL PHARMACIE DES VOSGES is estimated at 1 268 109 € (range 845 557€ - 1 711 021€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2020
180 transactions
845k€ 1268k€ 1711k€
1 268 109 € Range: 845 557€ - 1 711 021€
NAF 5 année 2020

Valuation method used

Net Income Multiple
89 729 € × 14.1x = 1 268 109 €
Range: 845 557€ - 1 711 022€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 180 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE DES VOSGES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE DES VOSGES

What is the revenue of SELARL PHARMACIE DES VOSGES ?

The revenue of SELARL PHARMACIE DES VOSGES in 2017 is 2.8 M€.

Is SELARL PHARMACIE DES VOSGES profitable?

Yes, SELARL PHARMACIE DES VOSGES generated a net profit of 90 k€ in 2020.

Where is the headquarters of SELARL PHARMACIE DES VOSGES ?

The headquarters of SELARL PHARMACIE DES VOSGES is located in STRASBOURG (67000), in the department Bas-Rhin.

Where to find the tax return of SELARL PHARMACIE DES VOSGES ?

The tax return of SELARL PHARMACIE DES VOSGES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE DES VOSGES operate?

SELARL PHARMACIE DES VOSGES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.